Biotech Adam Feuerstein and Damian Garde European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval
Biotech Damian Garde Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
Biotech Adam Feuerstein ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
Biotech Adam Feuerstein Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions
In the Lab Megan Molteni Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment
Biotech Matthew Herper, Damian Garde and Adam Feuerstein Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm
Health Andrew Joseph Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
First Opinion Jason Karlawish If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
The Aduhelm Files Damian Garde and Adam Feuerstein Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds
Biotech Jason Mast For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune
In the Lab Angus Chen Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s
In the Lab Megan Molteni In the blood of marathoning mice, scientists find clues to how exercise benefits the brain
Biotech Adam Feuerstein Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Adam's Take Adam Feuerstein In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Pharma Adam Feuerstein In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
First Opinion Jim Taylor Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark
Biotech Matthew Herper and Adam Feuerstein Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers
Biotech Damian Garde and Adam Feuerstein How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug
Biotech Adam Feuerstein, Damian Garde and Meg Tirrell An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug
Biotech Matthew Herper, Adam Feuerstein and Damian Garde Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process
Biotech Damian Garde and Adam Feuerstein Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment
Pharmalot Ed Silverman Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds
Biotech Damian Garde and Adam Feuerstein FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Biotech Adam Feuerstein and Damian Garde Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s
Biotech Adam Feuerstein A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Biotech Adam Feuerstein The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
Biotech Damian Garde Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
Biotech Jonathan Saltzman — Boston Globe Startup Arkuda targets rapidly advancing, rare form of dementia
First Opinion Dennis J. Selkoe Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs